UCB SA (EUR)
UCB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range86.32 | 87.98
52-Wk Range- | -
Last Close86.84
Mkt Cap (m)16,423.13
Dividend yield1.43
ISINBE0003739530
Volume294,911.00
Exchange VenueBRU

Company Profile

UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.

Key Information
Price/Earning22.04
Price/Book2.32
Price/Sales3.14
P/CF18.00
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

https://www.ucb.com

Financials

Income Statement
EUR201520162017201820192020
Revenue (m)3,876.004,178.004,530.004,632.004,913.00-
Operating Income (m)717.00967.001,137.001,163.001,073.00-
Net Income (m)623.00520.00753.00800.00792.00-
Basic EPS3.252.764.004.244.23-
Avg. Diluted Shares Outstanding (m)192.08188.37188.28188.48187.22-
Balance Sheet
EUR201520162017201820192020
Current Assets (m)2,838.002,331.002,677.002,950.003,295.00-
Non Current Assets (m)8,118.007,881.007,240.007,564.007,785.00-
Total Assets (m)10,956.0010,212.009,917.0010,514.0011,081.00-
Current Liabilities (m)3,061.002,418.001,949.002,238.002,394.00-
Total Liabilities (m)------
Total Equity (m)5,672.005,584.005,813.006,310.007,039.00-
Cash Flows
EUR201520162017201820192020
Operating Cash Flows (m)245.00427.00927.001,089.00882.00-
Capital Expenditure (m)-146.00-138.00-209.00-341.00-294.00-
Figures are quoted in EUR unless stated otherwise
-
No change
86.84
Last Price